The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback